|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: Cancer Pain - Physician survey highlights inadequacies in education and treatment
Datamonitor, Dec 2009, Pages: 247
Estimated to affect 6.7 million individuals across the seven major markets in 2009, the population of patients suffering from cancer pain is expected to increase in the future as elderly and minority populations drive the rising incidence of cancer. Coupling this patient dynamic with the inadequacies of current treatment, the cancer pain market remains an attractive prospect for drug manufacturers
Scope
- Snapshot of the cancer pain market based on a survey of 180 physicians, supplemented with interviews with seven key opinion leaders.
- Overview of cancer pain prevalence, including three cancer pain subtypes: neuropathic, non-neuropathic and breakthrough pain.
- Analysis of pharmacological treatment rates, first-line treatment trends at the class level and rate of progression to second-line treatment.
- Assessment of physician perception of three branded analgesics, satisfaction with available treatments and unmet needs.
Highlights of this title
Although almost all patients with severe cancer pain receive pharmacological treatment for their pain, the pharmacological treatment rates for mild and moderate cancer pain is sub-optimal. Additionally, over a fifth of breakthrough cancer pain patients do not receive pharmacological treatment.
Oncologists initiate and manage analgesic treatment in 45% and 44% of patients with cancer pain, respectively, across the seven major markets. It is therefore important for manufacturers of analgesic treatments for cancer pain to target oncologists in their marketing efforts.
Improved physician education represents the greatest unmet need in the treatment of all forms of cancer pain. This represents a key opportunity for manufacturers to provide education programs which inform physicians on methods of assessing pain, as well as the availability and appropriate use of analgesics for different subtypes of cancer pain.
Key reasons to purchase this title
- Understand differential treatment and unmet needs in key subtypes of cancer pain.
- Target physicians more effectively, through an understanding of prescribing behavior and its influences
- Use the interactive country-specific treatment trees and patient numbers to validate new product forecasting based on prevalence and treatment rates.
Customers who bought this item also bought
Pain Therapeutics - Drugs, Markets and Companies
The Global Pain Therapeutics Market, 4th Edition: Market Trends & R&D Insights
US Cancer Pain Report
Fentanyl - Products, Markets, Strategies and Opportunities
Neuropathic Pain: Competing Treatments and Market Entry Considerations
US Neuropathic Pain 2008 - 4th Edition: Market Potential Through 2018
Pipeline Insight: Moderate-to-Severe Acute Pain - Positive outlook for opioid-sparing analgesics
Neuropathic Pain: Emerging Drugs and Current Treatment Practices
Neuropathic Pain: Treatments and Prescribing Practices - A Global Survey 2009
Product Profiles: Moderate-To-Severe Acute Pain - Intensifying competition in breakthrough cancer pain market
|
|
|
|
